BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會


Joanne Lo

Session 6 – Pandemic Control after Vaccination (B)

Date:22 July (Thursday)
Time: 10:40 – 12:10 (GMT+8)

Joanne Lo

Director of Business Development
Senhwa Biosciences Inc.


With over 15 years experiences in the pharmaceutical industry and research studies, Joanne who received her science degree in biochemistry and international business management from McGill University, Canada, is skilled in new product evaluation, market research and analysis, business development for strategic alliance/in & out-licensing/co-development, and has well-established connections with pharmaceutical and biotech companies in the field worldwide. 


Speech title & Synopsis

A Worldwide Opportunity for Silmitasertib (CX-4945) as a Potential COVID-19 Therapy

Silmitasertib is a first-in-class potent and highly selective inhibitor for CK2. It was originally and primarily studied as an oncology new drug treating basal cell carcinoma, cholangiocarcinoma, and medulloblastoma for which Phase I and II studies are conducted. Due to its unique mechanism of being able to exert dual actions of tackling viral replication and cytokine storm by 1. blocking SARS-CoV-2-induced CK2 overactivation required for active viral replication and spread to nearby cells and 2. reducing cytokine storm severity by interrupting cytokine signaling pathway, Silmitasertib is regarded as a potential COVID-19 therapy. The most valuable trait of Silmitasertib is that SARS-CoV-2 virus mutations are unlikely to affect Silmitasertib anti-viral efficacy as it targets host protein kinase CK2. In summary, Silmitasertib is safe, easy for use via its oral dosage form and of notable potential treating COVID-19 due to its dual action of anti-viral and anti-inflammatory efficacy.